Report challenges preconceptions around combi-pack markets

25th May 2021

How unique are market forces for co-packaged mifepristone and misoprostol medical abortion packs (combi-packs)? Are they regarded by the commercial sector as just one more pharmaceutical product? Who exactly are the combi-pack supply chain actors? A new report presents lessons learned from the RHSC’s project ‘Leveraging the role of national distributors to accelerate access to medical abortion combi-packs in sub-Saharan Africa’; it debunks long-held myths and assumptions the community has built up around marketing combi-packs, takes a deep dive into Francophone Africa’s distinctive supply system, and offers practical advice.

Categories: New/Underused RH Technologies Caucus

You are currently offline. Some pages or content may fail to load.